The cardiac antihypertrophic effects of cyclic GMP-generating agents: An experimental framework for novel treatments of left ventricular remodeling

Vascular Disease Prevention

Volumn 2, Issue 2, 2005, Pages 151-157

  Deschepper, Christian F ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Bradykinin; Cyclic GMP; Guanylate cyclase; Left ventricular hypertrophy; Natriuretic peptides; Nitric oxide

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 MORPHOLINO 4,6 PYRIMIDINEDIAMINE; 4 [[4 CARBOXYBUTYL[2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL]BENZOIC ACID; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL STIMULATING AGENT; CARDIOVASCULAR AGENT; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME ACTIVATOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIM PROTEIN; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE RECEPTOR; NATRIURETIC PEPTIDE RECEPTOR AGONIST; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE ACTIVATOR; RECEPTOR PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SODIUM PROTON EXCHANGE PROTEIN; TROPONIN I; UNCLASSIFIED DRUG; VASODILATOR AGENT;

CALCIUM CURRENT; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; HEART HYPERTROPHY; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 16444370623     PISSN: 15672700     EISSN: None     Source Type: Journal    
DOI: 10.2174/1567270053507237     Document Type: Review

References (95)

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 1990; 322:1561-1566.
2. Devereux RB, de Simone G, Ganau A, Roman MJ. Left ventricular hypertrophy and geometric remodeling in hypertension: stimuli, functional consequences and prognostic implications. J Hypertens 1994; 12(suppl. 10):S117-S127.
3. de Simone G, Verdecchia P, Pede S, Gorini M, Maggioni AP. Prognosis of inappropriate left ventricular mass in hypertension. The MAV1 study. Hypertension 2002; 40:470-476.
4. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000; 35:580-586.
5. Verhaaren HA, Schicken RM, Mosteller M, Hewitt JK, Eaves LJ, Nance WE. Bivariate genetic analysis of left ventricular mass and weight in pubertal twins [the Medical College of Wisconsin twin study]. Am J Cardiol 1991; 68:661-668.
6. Garner C, Lecomte E, Visvikis S, Abergel E, Lathrop M, Soubrier F. Genetic and environmental influences on left ventricular mass. A family study. Hypertension 2000; 36:740-746.
7. Altmüller J, Palmer LJ, Fischer G, Scherb H, Wjst M. Genomewide scans of complex human diseases: true linkage is hard to find. Am J Hum Genet 2001; 69:936-950.
8. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996; 273:1516-1517.
9. Innes BA, McLaughlin MG, Kapuscinski MK, Jacob HJ, Harrap SB. Independent genetic susceptibility to cardiac hypertrophy in inherited hypertension. Hypertension 1998; 31:741-746.
10. Sebkhi A, Zhao L, Lu L, Haley CS, Nunez DJR, Wilkins MR. Genetic determination of cardiac mass in normotensive rats. Results from an F344xWKY cross. Hypertension 1999; 33:949-953.
11. Deschepper CF, Masciotra S, Zahabi A, Boutin-Ganache I, Picard S, Reudelhuber T. Functional alterations of the Nppa promoter are linked to cardiac ventricular hypertrophy in WKY/WKHA rat crosses. Circ Res 2001; 88:222-227.
12. Hamet P, Kaiser MA, Sun Y, et al. HSP27 locus cosegregates with left ventricular mass independently of blood pressure. Hypertension 1996; 28:1112-1117.
13. Pravenec M, Gauguier D, Schott J-J, et al. Mapping of quantitative trait loci for blood pressure and cardiac mass in the rat by genome scanning of recombinant inbred strains. J Clin Invest 1995; 96:1973-1978.
14. Tsujita Y, Iwai N, Tamaki S, Nakamura Y, Nishimura M, Kinoshita M. Genetic mapping of quantitative trait loci influencing left ventricular mass in rats. Am J Physiol 2000; 279:H2062-H2067.
15. John SWM, Kregc JH, Oliver PM, et al. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 1995; 267:679-681.
16. Oliver PM, Fox JE, Kim R, et al. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci USA 1997; 94:14730-14735.
17. Chusho H, Ogawa Y, Tamura N, et al. Genetic models reveal that brain natriuretic peptide can signal through different tissue-specific receptor-mediated pathways. Endocrinology 2000; 141:3807-3813.
18. Knowles JW, Esposito JW, Mao L, et al. Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. Proc Natl Acad Sci USA 2001; 107:975-984.
19. Kishimoto I, Rossi K, Garbers DL. A genetic model provides evidence that the receptor for atrial natriuretic peptide [guanylyl cyclase-A] inhibits cardiac ventricular myocyte hypertrophy. Proc Natl Acad Sci USA 2001; 98:2703-2706.
20. Holtwick R, van Eickels M, Skryabin BV, et al. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl-cylcase-A. J Clin Invest 2003; 111:1399-1407.
21. Boutin-Ganache I, Picard S, Deschepper CF. Distinct gene-sex interactions regulate adult rat cardiomyocyte width and length independently. Physiol Genomics 2002; 12:61-67.
22. Horio T, Nishikimi T, Yoshihara F, Matsuo H, Takishita S, Kangawa K. Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. Hypertension 2000; 35:19-24.
23. Silberbach M, Roberts CTJr. Natriuretic peptide signalling. Molecular and cellular pathways to growth regulation. Cellular Signalling 2001; 13:221-231.
24. Levin ER. Natriuretic peptide C-receptor: more than a clearance receptor. Am J Physiol 1993; 264:E483-E489.
25. Prins BA, Weber MJ, Hu R-M, Pedram A, Daniels M, Levin ER. Atrial natriuretic peptide inhibits mitogen-activated protein kinase through the clearance receptor. J Biol Chem 1996; 271(24):14156-14162.
26. Anand-Srivastava MB, Trachte GJ. Atrial natriuretic factor receptors and signal transduction mechanisms. Pharmacol Rev 1993; 45:455-497.
27. Kuhn M. Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A. Circ Res 2003;(93):700-709.
28. Li S, Washburn KA, et al. Developmental exposure to diethylbestrol elicits demethylation of estrogen-responsive lactoferrin gene in mouse uterus. Cancer Res 1997; 57:4356-4359.
29. Lin X, Hänze J, Heese F, Sodmann R, Lang RE. Gene expression in natriuretic peptide receptors in myocardial cells. Circ Res 1995; 77:750-758.
30. Rosenkranz AC, Hood SG, Woods RL, Dusting GJ, Ritchie RH. B-type natriuretic peptide prevents acute hypertrophic responses in the diabetic rat heart. Importance of cyclic GMP. Diabetes 2003; 52:2389-2395.
31. Takahashi N, Saito Y, Kuwahara K, et al. Angiotensin II-induced ventricular hypertrophy and extracellular signal-regulated kinase activation are suppressed in mice overexpressing brain natriuretic peptide in circulation. Hypertens Res 2003; 26:847-853.
32. Tamura N, Ogawa Y, Chusho H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA 2000; 97:4239-4244.
33. 0 C-type natriuretic peptide for rat netriuretic peptide receptor B. Mol Pharmacol 1995; 48:1046-1053.
34. Goy MF, Oliver PM, Purdy KE, et al. Evidence for a novel natriuretic peptide receptor that prefers brain natriuretic peptide over atrial natriuretic peptide. Biochem J 2001; 358:379-386.
35. Kapoun AM, Liang F, O'Young G, et al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-β in primary human cardiac fibroblasts. Circ Res 2004; 94:453-461.
36. Calderone A, Thaik CM, Takahashi N, Chang DLF, Colucci WS. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 1998; 101:812-818.
37. Silberbach M, Gorenc T, Hershberger RE, Stork PJS, Steyger PS, Roberts CTJr. Extracellular signal-regulated protein kinase activation is required for the anti-hypertrophic effect of atrial natriuretic factor in neonatal rat ventricular myocytes. J Biol Chem 1999; 274:24858-24864.
38. Rosenkranz AC, Woods RL, Dusting GJ, Ritchie RH. Antihypertrophic actions of natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP. Cardiovasc Res 2003; 57:515-522.
39. Zahabi A, Picard S, Fortin N, Reudelhuber TL, Deschepper CF. Expression of constitutively active guanylate cyclase in cardiomyocytes inhibits the hypertrophic effects of isoproterenol and aortic constriction on mouse hearts. J Biol Chem 2003; 278:47694-47699.
40. Lucas KA, Pitari GM, Kazerounian S, et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 2000; 52:375-413.
41. Massion PB, Feron O, Dessy C, Balliggand J-L. Nitric oxide and cardiac function. Circulation 2003; 93:388-398.
42. Barouch LA, Harrison RW, Skaf MW, et al. Nitric oxide regulates the heart by spatial confinment of nitric oxide synthase isoforms. Nature 2002; 416:337-340.
43. Scherrer-Crosbie M, Ullrich R, Bloch KD, et al. Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation 2001; 104:1286-1291.
44. Ichinose F, Bloch KD, Wu JC, et al. Pressure overload-induced LV hypertrophy and dysfunction in mice is exacerbated by congenital NOS3 deficiency. Am J Physiol 2003; 286:H1070-H1075.
45. Ozaki M, Kawashima S, Yamashita T, et al. Overexpression of endothelial nitric oxide synthase attenuates cardiac hypertrophy induced by chronic isoproterenol infusion. Circ J 2002; 66:851-856.
46. Ritchie RH, Marsh JD, Lancaster WD, Diglio CA, Schiebinger RJ. Bradykinin blocks angiotensin II-induced hypertrophy in the presence of endothelial cells. Hypertension 1998;[31]:39-44.
47. Rosenkranz AC, Hodd SG, Woods RL, Dusting GJ, Ritchie RH. Acute antihypertrophic actions of bradykinin in the rat heart. Importance of cGMP. Hypertension 2002; 40:498-503.
48. Ritchie RH, Schiebinger RJ, Lapointe MC, Marsh JD. Angiotensin II-induced hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide. Am J Physiol 1998; 275:H1370-H1374.
49. Emanueli C, Maestri R, Corradi D, et al. Dilated and failing cardiomyopathy in bradykinin B2 receptor knockout mice. Circulation 1999; 100:2359-2365.
50. Brull D, Dhamrait S, Myerson S, et al. Bradykinin B2BKR receptor polymorphism and left ventricular growth response. Lancet 2001; 358:1155-1156.
51. Xu L, Eu JP, Meissner G, Stamler JS. Activation of the cardiac calcium release channel [ryanodine receptor] by poly-S-nitrosylation. Science 1998; 279:234-237.
52. Cappola TP, Cope L, Cernetich A, et al. Deficiency of different nitric oxide synthase isoforms activates divergent transcriptional programs in cardiac hypertrophy. Physiol Genomics 2003; 14:25-34.
53. Feil R, Lohmann SM, de Jonge H, Walter U, Hofmann F. Cyclic GMP-dependent protein kinases and the cardiovascular system. Insights from genetically modeified mice. Circ Res 2003; 93:907-916.
54. Keilbach R, Ruth P, Hofmann F. Detection of cGMP dependent protein kinase isozymes by specific antibodies. Eur J Biochem 1992; 208:467-473.
55. Kumar R, Joyner RW, Komalavilas P, Lincoln TM. Analysis of expression of cGMP-dependent protein kinase in rabbit heart cells. J Pharmacol Exp Ther 1999; 291:967-975.
56. Fiedler B, Lohmann SM, SMolenski A, et al. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type 1 in cardiac myocytes. Proc Natl Acad Sci USA 2002; 99:11363-11368.
57. Frey N, McKinsey TA, Olson EN. Decoding calcium signals involved in cardiac growth and function. Nature Medicine 2000; 6:1221-1227.
58. 2+ current in rat ventricular myocytes. J Mol Cell Cardiol 1998; 30:1955-1965.
59. Liu QY, Karpinski E, Pang PK. The L-type calcium channel current is increased by alpha-1 adrenoceptor activation in neonatal rat ventricular cells. J Pharmacol Exp Ther 1994; 271:935-943.
60. Sei CA, Irons CE, Sprenkle AB, McDonough PM, Brown JH, Glembotski CC. The α-adrenergic stimulation of atrial natriuretic factor expression in cardiac myocytes requires calcium influx, protein kinase C, and calmodulin-regulated pathways. J Biol Chem 1991; 266:15910-15916.
61. 2+ channels suppresses activation of calcineurin and development of cardiac hypertrophy in spontaneously hypertensive rats. Hypertens Res 2002; 25:117-124.
62. Klein G, Drexler H, Schöder F. Protein kinase G reverses all isoproterenol induced changes of cardiac single L-type calcium channel gating. Cardiovasc Res 2000; 48:367-374.
63. Sumii K, Sperelakis N. cGMP-dependent protein kinase regulation of the L-type Ca2+ current in rat ventricular myocytes. Circ Res 1995; 77:803-812.
64. Sears CE, Bryant SM, Ashley EA, et al. Cardiac neuronal nitric oxide synthase isoform regulates myocardial contraction and calcium handling. Circ Res 2003; 92:e52-e59.
65. Aoki H, Izumo S, Sadoshima J. Angiotensin II activates RhoA in cardiac myocytes. A critical role of RhoA in angiotensin II-induced premyofibril formation. Circ Res 2004; 82:666-676.
66. Hoshijima M, Sah VP, Wang Y, Chien KR, Brown JH. The low molecular weight GTPase Rho regulates myofibril formation and organization in neonatal rat ventricular myocytes. Involvement of Rho kinase. J Biol Chem 1998; 273:7725-7730.
67. Charron F, Tsimilikis G, Arcand M, et al. Tissue-specific GATA factors are transcriptional effectors of the small GTPase RhoA. Genes & Develop 2001; 15:2702-2719.
68. Hattori T, Shimokawa H, Higashi M, et al. Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation 2004; 109:2234-2239.
69. Gudi T, Chen JC, Casteel DE, Seasholtz TM, Boss GR, Pilz RB. cGMP-dependent protein kinase inhibits serum-response element-dependent transcription by inhibiting Rho activation and functions. J Biol Chem 2002; 277:37382-37393.
70. Yuasa K, Michibata H, Omori K, Yanaka N. A novel interaction of cGMP-dependent protein kinase 1 with troponin T. J Biol Chem 1999; 274:37429-37434.
71. Layland J, Li J-M, Shah AM. Role of cyclic GMP-dependent protein kinase in the contractile response to exogenous nitric oxide in rat cardiac myocytes. J Physiol 2002; 540:457-467.
72. Ito N, Bartunek J, Spitzer KW, Lorell BH. Effect of nitric oxide donor sodium nitroprusside on intracellular pH and contraction in hypertrophied myocytes. Circulation 1997; 95:2303-2311.
73. Tajima M, Bartunek J, Weinberg EO, Ito N, Lorell BH. Atrial natriuretic peptide has different effects on contractility and intracellular pH in normal and hypertrophied myocytes from pressure-overloaded hearts. Circulation 1998; 98:2760-2764.
74. + exchange prevents hypertrophy, fibrosis, and heart failure in β1-adrenergic receptor transgenic mice. Circ Res 2002; 90:814-819.
75. + exchanger inhibition. Hypertension 2003; 41:1324-1329.
76. + exchanger inhibition. A new antihypertrophic tool. Circ Res 2002; 90:751-753.
77. Heineke J, Kempf T, Kraft T, et al. Downregulation of cytoskeletal muscle LIM protein by nitric oxide. Impact on cardiac myocyte hypertrophy. Circulation 2003; 107:1424-1432.
78. Diamond JA, Phillips RA. Regresion of left ventricular hypertrophy: are there preferred drugs? Curr Hypertens Rep 2004; 5:368-371.
79. Zhang R, Crump J, Reisin E. Regression of left ventricular hypertrophy is a key goal of hypertension management. Curr Hypertens Rep 2003; 5:301-308.
80. Sharp A, Mayet J. Regression of left ventricular hypertrophy: hoping for a longer life. J Renin Angiotensin Aldosterone Syst 2002; 3:141-144.
81. Diez J, Gonzales A, Lopez B, Ravassa S, Fortune MA. Effects of antihypertensive agents on the left ventyricle: clinical implications. Am J Cardiovasc Drugs 2001; 1:263-279.
82. Ishigai Y, Mori T, Ikeda T, Fukuzama A, Shibano T. Role of the bradykinin-NO pathway in prevention of cardiac hypertrophy by ACE inhibitor in rat cardiomyocytes. Am J Physiol 1997; 273:H2659-H2663.
83. 2 kinin receptor gene knockout mice. Circ Res 2001; 88:1072-1079.
84. Monopoli A, Ongini E, Cigola E, Olivetti G. The neutral endopeptidase inhibitor, SCH 34826, reduces left ventricular hypertrophy in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1992; 20:496-504.
85. Matsuoka H, Nakata M, Kohno K, et al. Chronic L-arginine administration attenuates cardiac hypertrophy in spontaneously hypertensive rats. Hypertension 1996; 27:14-18.
86. Schmidt P, Schramm M, Schroder H, Stasch JP. Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase. Eur J Pharmacol 2003; 16:167-174.
87. Friebe A, Koesling D. Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res 2003; 93:96-105.
88. Laufs U, Kilter H, Konkol C, Wassman S, Bohm M, Nickenig G. Impact of HMG CoA reductase on small GTPases in the heart. Cardiovasc Res 2002; 53:911-920.
89. Hayashidani S, Tsutsui H, Shiomi T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 105:868-873.
90. Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 2001; 104:982-985.
91. Nishikawa H, Miura S, Zhang B, et al. Stalins induce the regression of left ventricular mass in patients with angina. Circ J 2004; 68:121-125.
92. Hernández-Perera O, Pérez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-coA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101:2711-2719.
93. Porter KE, Turner NA, O'Regan DJ, Balmforth AJ, Ball SG. Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA. Cardiovasc Res 2004; 61:745-755.
94. Kang KK, Ahn GJ, Sohn YS, Kim WB. DA-8159, a new PDE5 inhibitor, attenuates the development of compensatory right ventricular hypertrophy in a rat model of pulmonary hypertension. J Int Med Res 2004; 31:517-528.
95. Rosenkranz AC, Dusting GJ, Ritchie RH. Hyperglycaemia abolishes the antihypertrophic efficacy of bradykinin in rat ventricular myocytes. Clin Exp Pharmacol Physiol 1999; 26:519-521.